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SUMMARY 
The temporal relationship between administration of cortisol and serum 17a- 
hydroxyprogesterone was investigated in five patients aged 9-19 years with con- 
genital adrenal hyperplasia due to 21-hydroxylase deficiency. There was marked 
variability in the 17a-hydroxyprogesterone response (determined hourly for 24 h) 
of individual patients to administration of cortisol. Mean concentration was less 
than 0.030 pmol/l in one patient but 0.519 pmol/l in another. Levels were higher in 
all patients while off treatment, and were greatest in those with salt-losing adrenal 
hyperplasia. Growth hormone secretion was not suppressed by treatment with cor- 
tisol. Withdrawal of cortisol for 3 days resulted in a significant decrease in the mean 
serum FSH/LH ratio and a rise in serum testosterone in all subjects. Episodic release 
of gonadotrophins persisted in the adolescent patients. 
Abnormalities of growth occur in patients with congenital adrenal hyperplasia (CAH). Exces- 
sive glucocorticoid treatment causes stunting, whereas inadequate therapy results in a rapid 
increase in height. It is frequently difficult to  determine the precise regimen which will sup- 
press androgen secretion without inhibiting linear growth. Recommended doses of cortisol* 
vary from 15 to 40 mg/m2/day (Laron & Pertzelan, 1968; Rappaport eta!., 1968). 
In the present study the temporal relationship between oral administration of cortisol 
and the serum concentration of 17a-hydroxyprogesterone (17-OHP) was studied during a 
24 h period to determine if the typical every-8-h dosage schedule provides adequate adrenal 
suppression. Serum concentrations of growth hormone (GH), total corticoids, follicle stimu- 
lating hormone (FSH), luteinizing hormone (LH), and testosterone were also determined. 
MATERIALS A N D  METHODS 
Subjects were five patients, aged 9-19 years, with CAH due to  21-hydroxylase deficiency. 
Subjects 1 and 2 were non salt-losers (Table 1). Patients were admitted to the Clinical Re- 
search Unit for 3 days on two separate occasions, in random sequence, at least 1 month 
* The following trivial names have been used: cortisol: 1 lp,l7,21-trihydroxy4-pregnane-3,20-dione; 21- 
deoxycortisol: 1 lp,l7-dihydroxy4-pregnene-3,20-dione; pregnanetriol: 5p-pregnane-3a,l7a,20a-triol; 
progesterone: 4-pregnene-3,20-dione; 17a-OH progesterone: 17a-hydroxy4-pregnene-3,20-dione; testo- 
sterone: 17p-hydroxy4-androsten-3a1e. 
Correspondence: Dr George E. Bacon, Department of Pediatrics, University of Michigan, Ann Arbor, 
Michigan, U.S.A. 
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apart. During one hospitalization, treatment with cortisol was continued as usual. Dose 
ranged from 19 t o  24 mg/m2/day, similar to the 25  mg/m2/day recommended by Brook 
et al. (1974). Approximately one quarter of the daily amount was given at 08.00 hours, a 
quarter at 16.00 hours and a half at 24.00 hours. In the other hospitalization, cortisol was 
withdrawn 1 day prior to  admission. Patients requiring mineralocorticoid continued to re- 
ceive 9a-fluoro-hydrocortisone during both admissions. 
The study protocol was approved by the Committee to  Review Grants for Clinical Re- 
search and Investigation Involving Human Beings, University of Michigan Medical Center. 
'Informed Consent' forms were signed by each patient and parent with full knowledge of 
the procedure. 
Table 1. Clinical data, serum 17a-hydroxyprogesterone, and growth hormone 
Cortisol dose Growth hormone 
'Area' 17-OHP* 
Patient Sex CA/BA mg/day mg/m2/day f w N l )  "'I ua-h x lo-' 
1 M 8.9/12.5 25 
2 F 12.0/11.0 25 
3 F 13.8/15.0 30 
4 F 14.3/adult 30 
5 F 18.8/adult 35 
(5-5-1 5)t 
(5-5-15) 
(7.5-7.5-15) 
(7.5-7.5-1 5) 
(10-10-1 5) 
20 Rx 
19 Rx < 
19 Rx 
21 Rx 
24 Rx 
No Rx 
No Rx 
No Rx 
No Rx 
No Rx 
0.036c0.006 
0.097r0.017 
:0.030 
0.201r0.014 
0.061 rO.008 
0.450+0.030 
0.099k0.008 
0.381r0.022 
0.5 19r0.044 
0.949?0.055 
1.3r0.3 
l . l i 0 .4  
3.350.9 
3.0r0.5 
2.8k0.6 
2 .O+ 0.4 
1.7k0.4 
0.9r0.2 
4.2k0.5 
2.0k0.2 
27.8 
22.8 
78.5 
77.9 
59.4 
43.0 
37.1 
22.1 
100.0 
46.0 
CA = Chronologic age (in years). BA = Bone age. 
* Mean valuecSE for 24 h.  Mean serum 17-OHP concentration in control group <0.030 /.tmol/l. Mean 
17-OHP for patients 1 and 2 (non-salt-losers) = 0.149c0.086 (SD) 1-1. 0.599r0.257 pmol/l (P<O.Ol) for 
patients 3-5 (salt-losers) while off treatment. 
t ( ) = amount of individual doses. 
Serum samples for 17-OHP and total corticosteroids were obtained hourly for 24 h 
during the third day of each admission. Samples for GH were obtained every hour from 
08.00 to  15.00 hours and at 30 min intervals from 15.00 to  08.00 hours. Serum FSH and 
LH were determined every 20 min between 08.00 and 15.00 hours and hourly from 24.00 
until 08.00 hours. Serum testosterone was measured at 08.00 hours on the day of the study. 
Urinary 24 h excretion of 17-oxosteroids (17-0S), 17-hydroxycorticosteroids (17 .OHCS) 
and creatinine were determined for three consecutive days during both hospitalizations. 
Serum samples for determination of 17-OHP were prepared by a modification of the 
methods of Franks (1 974) and Pham-Huu-Trung er al. (1973). Serum (0.2 ml) was extracted 
with 2.0 ml of ch1oroform:carbon tetrachloride (1 : 2 )  and 5 ml of water. 1 ml of the organic 
layer was dried, taken up three times in 0.1 ml of dichloromethane, and applied to  a 1 X 
15 cm column (with 100 ml reservoir) containing 2.15 g of Sephadex LH20 in dichloro- 
methane. The column was eluted with 100 ml of dichloromethane. Correction for recovery 
(-85%) was determined for each assay. The 5-15 ml fraction was dried and dissolved in 
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2.0 ml of ethanol. Aliquots of 5 ,  10, 25 and 50 pl, in duplicate, were found to be appro- 
priate for assay. 
The samples were quantitated by radioimmunoassay essentially as described by Abraham 
et al. (1971a). The antiserum, obtained from Dr Abraham, was prepared by immunizing a 
ewe with 1 1 -deoxycortisol-21 -monosuccinate-human serum albumin. Data regarding speci- 
ficity have been published previously (Abraham et al., 1971 b). In our laboratory, no  inter- 
ference from 21-deoxycortisol occurred. The antiserum reacted with progesterone, but some 
of this hormone was removed by the purification steps. Progesterone carried through the 
assay caused an effect equivalent to  about 50% that of an equal amount of 17-OHP. Cortisol 
was removed by the purification steps. Intra-assay coefficients of variation averaged 7.1% 
for a low control serum and 11 .O% for a high control serum. 
Sixteen children, aged 6-19 years, without known adrenal pathology, had a mean 17- 
OHP concentration of less than 0.030 pmol/l. The method used would not be adequate for 
the study of unaffected subjects, since average values in normal prepubertal children are less 
than 0.002 pmol/l (Lippe et al., 1974). However,it was satisfactory for evaluation of patients 
with CAH. In the present study, all subjects had mean 17-OHP concentrations greater than 
0.030 pmol/l, with the exception of patient 2 during the treatment period. The assay could 
be improved by increasing the size of the serum sample, but limitations on withdrawal of 
blood precluded this possibility. 
Total corticosteroids were measured by Murphy’s (1967) method using an antiserum 
rather than cortisol binding globulin. Serum GH was determined by double antibody radio- 
immunoassay (Youlton et al., 1969). 
Serum FSH and LH were measured by radioimmunoassays (Lee et al., 1970; Midgley, 
1966, 1967; Midgley & Jaffe, 1971). The mean intra-assay coefficients of variation at 20% 
and 80% inhibition were 5.2% k0.2 (SE) and 10.4% f0.3 (SE) for the FSH assay (n = 24), 
and 5.5% i0.3 (SE) and 11 .O% k0.6 (SE) for the LH assay (n = 20). The sensitivities of the 
gonadotrophin assays, determined as the amount of 2nd-IRP-HMG in miu/tube predicted to 
give the mean activity associated with the buffer control tube, less two standard deviations, 
averaged 0.27 miu 20.03 (SE) for FSH and 0.20 miu M.04 (SE) for LH. Duplicate 200 pl 
(FSH) or 100 pl (LH) samples were used. 
Serum testosterone was measured by a modification of the method of Ismail et al. (1 972). 
Ammonium sulphate precipitation was replaced by extraction with benzene:hexane (1 :2). 
An antiserum raised in rabbits against testosterone-1 1-hemisuccinate conjugated to  bovine 
serum albumin, and testosterone-I 1 -hemisuccinate-[ ‘’ST] tyrosine-methyl ester were used as 
the first antibody and radiolabeled ligand respectively. Assay sensitivity was 10 pg/tube. 
Gonadotrophin and testosterone calculations were performed by the computer program 
described by Duddleson et al. (1972). 
Urinary 17-0s  and 17-OHCS were determined by standard methods (Zimmerman, 1955; 
Silber & Porter, 1954). 
The data were analysed by Student’s unpaired ‘t’ test. Areas under the GH curves were 
determined by triangulation. 
RESULTS 
1 7a-Hydroxyprogesterone and total corticosteroids 
Serum 17-OHP and total corticoid concentrations for each patient are presented in Figs. 
1-5. There was striking variability in the 17-OHP response of individual patients to adminis- 
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tration of cortisol (Table 1). Mean 17-OHP level was less than 0.030 pmol/l in patient 2 
during treatment, but 0.519 pmol/l in patient 5. In subject 5 (Fig. 5 ) ,  and possibly in subject 
4 (Fig. 4), the results suggested a reciprocal relationship between total corticoid and 17-OHP 
levels. 
Concentrations of 17-OHP were higher in all patients while off treatment, and were 
greatest in those with salt-losing CAH. A circadian variation was observed in each case. 
The increased corticoid concentrations obtained following oral administration of cortisol 
provided evidence that the drug was ingested and absorbed. 
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Fig. 1. Patient 1, male, 8 years 11 months. 
Figs. 1-5. Serum 17-OHP and corticosteroid (cortisol) concentrations in five patients during 
cortisol therapy (upper panel), and after treatment had been discontinued for 3 days (lower 
panel). Arrows denote times of cortisol administration during treatment study. 
t 
Growth hormone. GH concentrations are depicted in Table 1 and Fig. 6 .  Treatment and 
non-treatment patterns were remarkably similar in all patients. Increased daytime values 
during treatment in patient 5 may have been secondary to difficulties in maintaining a patent 
intravenous cannula. There was no evidence to suggest that cortisol suppressed GH secretion. 
Indeed, mean GH concentrations and areas under the GH secretory curves were slightly 
greater in all patients during treatment. 
FSH and LH. Serum FSH patterns are illustrated in Table 2 and Fig. 7. In general, FSH 
concentrations fluctuated minimally. Mean FSH values were significantly greater (P<0.025) 
during the treatment study in all but one patient (No. 3); the differences were more ap- 
parent during the daytime sampling period. Patients 1, 2 and 5 failed to show consistent 
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differences between nocturnal and daytime FSH concentrations. Mean nocturnal FSH con- 
centrations of patients 3 and 4 were significantly greater (P<0.025) than daytime values 
during both studies. 
Serum LH patterns are shown in Table 2 and Figs. 8 and 9. LH concentrations were 
relatively constant throughout the day in the two youngest patients. In the three oldest 
Fig. 6 .  Serum GH concentrations in five patients with CAH during cortisol therapy ( 0 )  and 
after treatment had been discontinued for 3 days (0).  Arrows denote times of cortisol ad- 
ministration during treatment study. 
patients, LH was secreted episodically during both studies (Midgley & Jaffe, 1971); however, 
the amplitudes of the secretory bursts were greater after cortisol had been withdrawn for 3 
days. In contrast to  the minor changes in FSH, mean serum LH was significantly greater 
(P<O.Ol) after cortisol withdrawal in all patients except No. 2. Mean nocturnal LH values 
were consistently greater than daytime values in patients 4 and 5 (fYO.05). Analysis of the 
lable L. Serum I-SH, LH, I-SH/LH ratio, testosterone, and urinary 17-ketosteroids 
Patient 
FSH* LH* FSH/LH* Testosterone? 17-0SS 
(iu/l) (iu/l) (nmol/l) (rrmol/day) 
1 Treatment 
2 Treatment 
3 Treatment 
4 Treatment 
5 Treatment 
No treatment 
N o  treatment 
No treatment 
No treatment 
No treatment 
3.2k0.14 3.6k0.2 
2.7k0.13 4.5r0.2 
6.5k0.6 3.1k0.2 
5.2t0.3 3.3t0.1 
7.6t0.2 13.4t0.7 
7.9c0.4 22.2k1.6 
13.3k0.6 9.7k0.7 
10.6k0.9 15.0k1.4 
7.6c0.3 16.8cl.2 
6.120.2 26.8k1.5 
0.9 7 ~ 0 . 0 6  
0.61+0.04 
2.42c0.4 
1.6620.1 
0.6 1 c0.03 
0.3950.02 
1.15+0.09 
0.75k0.04 
0.50?0.03 
0.25t0.02 
10.4 
24.3 
3.5 
10.4 
13.9 
48.5 
48.5 
86.7 
58.9 
72.8 
22.5 
21.4 
13.2 
39.5 
39.2 
130.0 
69.3 
129.7 
54.8 
210.8 
* MeankSE. 
t 08.00 hours sample. Normal values: prepubertal children <7.0 nmol/l, premenopausal women 3.5- 
$ Study day only. 
40.0 nmol/l. 
NO. 5 ($ 18E years 
2o r 
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I t  t t Time (hours1 
Fig. 7. Serum FSH concentrations in five patients with CAI1 during cortisol therapy (*) and 
after treatment had been discontinued for 3 days (0). Arrows denote times of cortisol ad- 
ministration during treatment study. 
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FSH/LH ratio of all serum samples revealed a significantly lower (P<0.05) mean value 
during the non-treatment study in all patients. 
Testosterone. Serum testosterone concentrations were lower in all patients while on  
treatment (Table 2), but the difference was not significant and only two subjects (Nos. 2 
and 3) had values in the normal range for their age and sex. 
Urinaly 17-oxosteroids and 17-hydroxysteroids. During the non-treatment period, daily 
17-0s  values tended to increase progressively through the fourth day after withdrawal of 
cortisol. Treatment with cortisol caused variable suppression of 17-0s  (Table 2) but resulted 
in a significant decrease (lV0.025) for the group. Considerable day-to-day fluctuation oc- 
curred in two subjects. Values ranged from 54.8 to 102.6 pmol/day in patient 5 even though 
the dose of cortisol was constant for the 3 day period. 
Urinary 17-OHCS excretion was relatively low (X = 3.9 pmol/m2/day) for the five sub- 
jects during the non-treatment period and was higher in the non-salt-losers (SS = 5.8 vs. 
2.8 p mol/m2/day, P<O.O5). Mean excretion during therapy (?i= 20.4 pmol/m2) was about 
twice the average normal value (8.3 pmol/m2), consistent with the fact that the adminis- 
tered dose of cortisol was roughly double the physiologic production rate of 33.1 pmol/m2 
(Kenny et al., 1970). 
DISCUSSION 
Concentrations of 17-OHP varied considerably among untreated patients, but were almost 
always above the normal range for the method employed. The three subjects with salt-losing 
CAH had the highest values, consistent with the hypothesis that the metabolic block is more 
severe in this form of the disease (Bongiovanni & Eberlein, 1958). All patients demonstrated 
a diurnal variation. 
Patient 5, a 19-year-old girl with salt-losing CAH, demonstrated the poorest control. Her 
mineralocorticoid had been successfully withdrawn during adolescence, and therefore was 
not administered during the study. Hughes & Winter (1976) have recently noted that even 
slightly inadequate mineralocorticoid therapy, manifested by elevated plasma renin activity 
with normal electrolytes, may cause increased 17-OHP despite appropriate cortisol replace- 
ment. These authors also reported normal 17-OHP levels in eight of eleven children treated 
with at least 20 mg/m2/day of cortisol. In the others, 17-OHP concentrations were elevated 
to varying degrees. Control was improved by increasing the dose (in one patient) or simply 
modifying the administration schedule. 
In earlier studies, Lippe et al. (1974) obtained serial 17-OHP determinations for approxi- 
mately 3 days in two subjects. Periodic administration of oral cortisone resulted in con- 
tinuous adrenal suppression in one well-controlled patient. In the other subject, 17-OHP 
concentrations were elevated prior to  treatment, but a substantial decrease was noted follow- 
ing oral cortisone. Atherden et al. (1972) also determined serial 17-OHP concentrations in 
three children with CAH. A marked circadian variation was observed in the two untreated 
patients. One subject, who was treated with cortisone acetate every 6 h ,  likewise demon- 
strated considerable variation, with peak 17-OHP levels of about 0.300 pmolll. 
Patients with CAH often receive oral cortisol three times daily or every 8 h. The results of 
the present study suggest that more frequent administration may be required for adequate 
suppression of serum 17-OHP in some patients, even when the total daily dose approximates 
double the normal physiologic production rate. Possibly, the use of a delayed-release prep- 
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aration of cortisol, or of a synthetic substitute with a longer half-life, would provide better 
control with less steroid. However, it has been reported that growth suppression is greater 
with some of the steroid analogs than with the naturally occurring hormone (Laron & 
Pertzelan, 1968), a potential disadvantage in patients who have not reached their final height. 
Recently, McKenna et al. (1976) have suggested that suppression of precursor steroids t o  
normal necessarily requires supraphysiologic amounts of cortisol; the alternative is to  permit 
a mild excess of precursor steroid secretion, with resultant elevation of urinary 17-0s  and 
pregnanetriol. 
Serial 17-OHP determinations were helpful in assessing the degree of control of CAH 
during a 24 h period and in demonstrating the relationship to  exogeneous cortisol but this 
procedure obviously is impractical for routine use. Because of the frequent changes in con- 
centration, the usefulness of a single random determination of 17-OHP in prediciting the 
status of a treated patient has been questioned (Lippe et al., 1974). However, Hughes & 
Winter (1976) found good agreement between the 08.00,12.00,18.00 or 24.00 hours serum 
17-OHP concentration and urinary pregnanetriol excretion in the great majority of cases. In 
one of our patients (No. 2), 17-0s  excretion and the first 17-OHP measurement obtained at 
08.00 hours were normal. In the others, both values were elevated. Concordance was noted 
in all but one subject using the 17-OHP concentration obtained at either 09.00 hours, or at 
08.00 hours at the conclusion of the study day. Therefore, serum 17-OHP measurements 
obtained at specified times would appear to be reasonably reliable for monitoring therapy. 
In addition, 17-OHP determinations have proven useful in the diagnosis of CAH (Barnes & 
Atherden, 1972; Franks, 1974; Youssefhajadian & David, 1975). 
The total corticosteroid concentrations were relatively high in patient 5 during the non- 
treatment period (X = 0.455 pmol/l). This was probably due to interference from cortisol 
precursors, primarily 2 1-deoxycortisol, since urinary 17-OHCS excretion on the day was 
only 4.1 pmol. On the other hand, Fukushima et al. (1975) have demonstrated normal cor- 
tisol production rates (CPR) in CAH. They postulated that patients with severe enzyme de- 
ficiency synthesize adequate amounts of cortisol by increasing adrenocorticotrophic hor- 
mone secretion. The CPR in one of their subjects was in the high normal range. 
Our data suggest that GH secretion in children with CAH is adequate and that the noc- 
turnal release is not suppressed by treatment with cortisol. Vasquez et al. (1972) made a 
similar observation in a 14-year-old girl. Therefore, the impaired linear growth sometimes 
observed in these patients probably is not a result of abnormal GH secretion. 
Finkelstein et al. (1973) reported that untreated patients with CAH secreted more GH 
than normal prepubertal children of comparable age, and suggested that the rapid growth of 
these subjects might be related to  increased GH. The GH concentrations of the untreated 
patients reported here did not appear to  be elevated, but concurrent measurements in un- 
affected children were not performed. 
In the current study, withdrawal of glucocorticoid therapy for 3 days significantly altered 
the serum concentrations and secretory patterns of gonadotrophins in the two prepubertal 
(Nos. 1 and 2) and three pubertal (Nos. 3-5) children with CAH. As illustrated by the 
changes in 17 -0s  excretion, serum 17-OHP and testosterone concentrations, adrenal sex 
steroid secretion rose during the non-treatment study. Glucocorticoid withdrawal, however, 
significantly decreased the FSH/LH ratio in all patients. This change contrasts sharply with 
the expected negative feedback effects of sex steroids on gonadotrophin secretion and with 
the minimal effects of adrenal suppression with dexamethasone on serum gonadotrophins in 
adult subjects (Faiman & Winter, 1971; Kim etal., 1974). The mechanism(s) of the differen- 
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tial modulation of FSH and LH secretion by increased concentrations of adrenal sex steroids 
is not readily apparent. 
Boyar et QI. (1973) studied two untreated boys with CAH and advanced skeletal matura- 
tion. In both patients there was episodic secretion of gonadotrophins with increased LH 
release during sleep. These authors postulated that prolonged secretion of increased amounts 
of adrenal steroids may stimulate the maturation of the hypothalamic-pituitary-gonadal axis. 
The 90-120 min periodicity of LH bursts found in our three oldest patients is similar to  re- 
ported data in normal adults, pubertal children, and hypogonadal patients (Johnson, 1974; 
Kelch et ~ l . ,  1973; Midgley & Jaffe, 1971; Nankin & Troen, 1971). The nocturnal rise in 
gonadotrophin concentrations in these patients resembles the patterns reported in early to  
mid-pubertal children (Boyar et d., 1972). The current study therefore is in agreement with 
the findings of Boyar et aZ.(1973) and lends support t o  their speculation. On the other hand, 
Wentz et al. (1976) have recently reported a blunted peak LH response to  gonadotrophin- 
releasing hormone in two pubertal females with poorly controlled CAH. Thus, although we 
demonstrated a decreased FSH/LH ratio following short-term withdrawal of cortisol, lack of 
treatment for a longer period may have resulted in the expected suppression of serum 
gonadotrophins. 
The altered gonadotrophin secretory patterns noted in our patients after relatively brief 
withdrawal of glucocorticoid therapy could conceivably explain, in part, the high incidence 
of amenorrhoea and irregular menses in females with CAH. Follicular development and sub- 
sequent ovulation might be impaired by the decreased FSH/LH ratio. Similarly, decreased 
FSH/LH ratios have been reported by Yen et QI. (1 974) in selected patients with polycystic 
ovarian disease, another condition often associated with increased adrenal sex steroid secre- 
tion. This study suggests the need for continuous, good control of adrenal steroid produc- 
tion in CAH t o  allow the development of regular menstrual cycles. 
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